Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh Ellis

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Cell Reports|November 21, 2019
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerJustin H Hwang, Ji-Heui Seo, Michael L Beshiri, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerJohn T Phoenix, Audris Budreika, Devin A Schmeck, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Nature Communications|September 27, 2019
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC programDavid P Labbé, Giorgia Zadra, Meng Yang, et al.
Nature Communications|October 2, 2021
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancerPaloma Cejas, Yingtian Xie, Alba Font-Tello, et al.
Nature Communications|January 19, 2019
ONECUT2 is a driver of neuroendocrine prostate cancerHaiyang Guo, Xinpei Ci, Musaddeque Ahmed, et al.
Nature Communications|March 31, 2021
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSylvan C Baca, David Y Takeda, Ji-Heui Seo, et al.
Nature Cancer|April 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.
Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
Nature Communications|February 6, 2021
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinomaZiad Bakouny, David A Braun, Sachet A Shukla, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cell Reports|November 21, 2019
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerJustin H Hwang, Ji-Heui Seo, Michael L Beshiri, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerJohn T Phoenix, Audris Budreika, Devin A Schmeck, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Nature Communications|September 27, 2019
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC programDavid P Labbé, Giorgia Zadra, Meng Yang, et al.
Nature Communications|October 2, 2021
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancerPaloma Cejas, Yingtian Xie, Alba Font-Tello, et al.
Nature Communications|January 19, 2019
ONECUT2 is a driver of neuroendocrine prostate cancerHaiyang Guo, Xinpei Ci, Musaddeque Ahmed, et al.
Nature Communications|March 31, 2021
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSylvan C Baca, David Y Takeda, Ji-Heui Seo, et al.
Nature Cancer|April 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.
Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
Nature Communications|February 6, 2021
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinomaZiad Bakouny, David A Braun, Sachet A Shukla, et al.
Pageof 7